Athira Pharma (ATHA)

Company Profile

Athira, headquartered in the Seattle area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. Athira aims to provide rapid cognitive improvement and alter the course of neurological diseases with its novel mechanism of action. Athira is currently advancing its lead therapeutic candidate, ATH-1017, a novel small molecule for Alzheimer’s and Parkinson’s dementia.

Company profile

Ticker

ATHA

Exchange

Website

Incorporated

Location

Fiscal year end

Sector

Manufacturing > Biological Product (except Diagnostic) Manufacturing

Industry (SIC)

Biological Products, (No Diagnostic Substances)

AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Exelixis • Sana Biotechnology • Bio-Techne • Ginkgo Bioworks ...

Former names

M3 Biotechnology, Inc.

SEC CIK

0001620463

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

ATHA stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

8-K

Entry into a Material Definitive Agreement

6 Jan 23

424B5

Prospectus supplement for primary offering

6 Jan 23

8-K

Amendments to Articles of Incorporation or Bylaws

10 Nov 22

Athira Pharma Reports Third Quarter 2022 Financial Results and Recent Clinical and Corporate Updates

10 Nov 22

8-K

Results support potential clinically meaningful activity of fosgonimeton without background therapy and mitigate program risk

15 Aug 22

Athira Pharma Reports Second Quarter 2022 Financial Results and Recent Clinical and Corporate Updates

15 Aug 22

8-K

Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease

22 Jun 22

8-K

Submission of Matters to a Vote of Security Holders

24 May 22

Transcripts

ATHA

Earnings call transcript

2021 Q4

24 Mar 22

Latest ownership filings

View all

FRANKLIN RESOURCES INC

Financial summary

Financial statements Chart ATHA financial data

Quarter (USD)	Sep 22	Jun 22	Mar 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	87.26 mm	87.26 mm	87.26 mm	87.26 mm	87.26 mm	87.26 mm
Cash burn (monthly)	2.67 mm	1.67 mm	8.04 mm	7.49 mm	7.21 mm	6.25 mm
Cash used (since last report)	10.99 mm	6.88 mm	33.11 mm	30.82 mm	29.69 mm	25.72 mm
Cash remaining	76.27 mm	80.38 mm	54.15 mm	56.44 mm	57.57 mm	61.54 mm
Runway (months of cash)	28.6	48.1	6.7	7.5	8.0	9.8

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2022

ATHA institutional ownership history Ownership history

58.0% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	90	105	-14.3%
Opened positions	15	21	-28.6%
Closed positions	30	29	+3.4%
Increased positions	32	37	-13.5%
Reduced positions	14	23	-39.1%

13F shares	Current	Prev Q	Change
Total value	62.79 mm	358.26 mm	-82.5%
Total shares	21.93 mm	23.09 mm	-5.0%
Total puts	82.40 k	1.18 mm	-93.0%
Total calls	617.70 k	3.78 mm	-83.7%
Total put/call ratio	0.1	0.3	-57.1%

Largest owners	Shares	Value	Change
Perceptive Advisors	4.80 mm	$14.25 mm	0.0%
BLK Blackrock	2.59 mm	$7.70 mm	+4.3%
Ra Capital Management	1.88 mm	$5.58 mm	0.0%
Vanguard	1.83 mm	$5.44 mm	+13.7%
Pathstone Family Office	1.82 mm	$5.39 mm	+7.5%
Baker Bros. Advisors	1.04 mm	$3.09 mm	0.0%
Venrock Healthcare Capital Partners II	1.00 mm	$0.00	0.0%
Bristlecone Advisors	700.93 k	$2.08 mm	0.0%
Geode Capital Management	592.70 k	$1.76 mm	+3.1%
BAC Bank Of America	489.25 k	$1.45 mm	+14.2%

Largest transactions	Shares	Bought/sold	Change
STT State Street	0.00	-910.38 k	EXIT
GS Goldman Sachs	159.70 k	-421.30 k	-72.5%
Citadel Advisors	440.78 k	-408.21 k	-48.1%
Two Sigma Advisers	347.40 k	+241.80 k	+229.0%
Renaissance Technologies	235.00 k	+235.00 k	NEW
Vanguard	1.83 mm	+221.45 k	+13.7%
Logos Global Management	0.00	-220.00 k	EXIT
Aqr Capital Management	219.47 k	+219.47 k	NEW
Jefferies	0.00	-201.26 k	EXIT
Susquehanna International	62.80 k	-175.26 k	-73.6%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

ATHA insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
27 Jan 23	Mark James Litton	Stock Option Common Stock	Grant	Acquire A	No	No	4.11	425,000	1.75 mm	425,000
19 Jan 23	Kevin Church	Stock Option Common Stock	Grant	Acquire A	No	No	3.37	150,000	505.50 k	150,000
19 Jan 23	Rachel Lenington	Stock Option Common Stock	Grant	Acquire A	No	No	3.37	200,000	674.00 k	200,000
19 Jan 23	Glenna Mileson	Stock Option Common Stock	Grant	Acquire A	No	No	3.37	150,000	505.50 k	150,000
19 Jan 23	Hans Moebius	Stock Option Common Stock	Grant	Acquire A	No	No	3.37	200,000	674.00 k	200,000
18 Nov 22	Mark James Litton	Common Stock	Grant	Acquire A	No	No	2.74	662	1.81 k	129,217
18 Nov 22	Kevin Church	Common Stock	Grant	Acquire A	No	No	2.74	657	1.80 k	62,052